OPKO Health

Core Testing And FDA Approvals Will Strengthen Diagnostics

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

25 Mar 25

Updated

06 Aug 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-15.2%

1.5%

-15.2%

1.5%

You can edit this narrative until Aug 6 2:25 AM. Then, changes will post as Updates.

Author's Valuation

US$3.6363.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates6

Shared on 06 Aug 25

Fair value Decreased 9.19%

The consensus price target for OPKO Health has been reduced, primarily reflecting lower revenue growth expectations and a higher discount rate, resulting in a new fair value estimate of $3.62. What's in the News Issued 2025 revenue guidance of $640–$660 million.

Shared on 01 May 25

Fair value Increased 22%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 18%

AnalystConsensusTarget has decreased revenue growth from 6.0% to 4.9%, decreased future PE multiple from 123.3x to 76.6x and decreased shares outstanding growth rate from 0.1% to -0.0%.

AnalystConsensusTarget Fair Value

US$3.63

63.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

2.17%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$40.64m

Earnings '28

105.54x

PE Ratio '28

US$4.29b

Market Cap '28

US$4.29b

Market Cap '28

972.42m

No. shares '28

US$4.41

Share Price '28

US$4.41 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$3.62

Fair Value '25